Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Triptorelin

Decapeptyl, Trelstar, Gonapeptyl, Pamorelin

Quick Stats
Studies 178
Trials 100
Score 2
2024 pubmed

Back to the Future: Is GnRHa Treatment in Transgender and Gender Diverse Adolescents Only an Extended Evaluation Phase?

Fisher. Alessandra D AD; Ristori. Jiska J; Romani. Alessia A; Cassioli. Emanuele E; Mazzoli. Francesca F; Cocchetti. Carlotta C; Pierdominici. Marina M; Marconi. Matteo M; Ricca. Valdo V; Maggi. Mario M; Vignozzi. Linda L; Castellini. Giovanni G

Key Findings

  • Triptorelin effectively halts puberty progression in transgender adolescents
  • Psychological distress rises before treatment but improves significantly during GnRHa therapy
  • Physical and hormonal changes during treatment correlate with reduced suicidality, anxiety, and body‑image concerns

Practical Outcomes

  • For those exploring hormone modulation, the data suggest GnRHa can provide mental‑health benefits when used as part of gender‑affirming care, not just as a diagnostic pause. The protocol involved monthly intramuscular injections for 3–12 months, showing measurable hormone and body changes that align with improved well‑being. However, the findings are specific to transgender youth and not directly applicable to general longevity or performance optimization.

Summary

The study shows that giving the hormone blocker triptorelin to transgender teens stops puberty and, after a few months, improves mood, reduces anxiety, depression, and thoughts of suicide. The mental health boost seems linked to the physical changes caused by the drug, like lower sex hormones and changes in body shape.

Abstract

The role of body modifications induced by gonadal suppression in transgender and gender diverse adolescents on psychological functioning has not yet been evaluated. The main aim of the present study was to explore several hormone, physical and psychological functioning changes during gonadotropin-releasing hormone analog (GnRHa) treatment in transgender and gender diverse adolescents (TGDAs). The potential relationship between the physical and hormone effects of GnRHa and psychological well-being, along with its magnitude, was assessed for the first time. This prospective multidisciplinary study included 36 TGDA (22 assigned female at birth, and 14 assigned male at birth) who received psychological assessment followed by triptorelin prescription after referring to the Florence Gender Clinic. This study consisted of 3 time points: first referral (T0), psychological assessment (T1); and treatment with intramuscular injections of triptorelin for 3 up to 12 months (T2). Psychometric questionnaires were administered at each time point, and clinical and biochemical evaluations were performed at T1 and T2. The following results were found: (1) GnRHa showed efficacy in inhibiting puberty progression in TGDAs; (2) an increase in psychopathology was observed before starting GnRHa (T1) compared with baseline levels; (3) during GnRHa treatment (T2), a significant improvement in psychological functioning, as well as decrease in suicidality, body uneasiness, depression, and anxiety levels were observed; (4) hormone and physical changes (in terms of gonadotropin and sex steroid levels, height and body mass index percentiles, waist-hip ratio, and acne severity) observed during triptorelin treatment significantly correlated with a reduction in suicidal ideation, anxiety, and body image concerns. Psychological improvement in TGDA on GnRHa seems to be related to the objective body changes induced by a GnRHa. Therefore, the rationale for treatment with a GnRHa may not only be considered an extension of the evaluation phase, but also the start of a medical (even if reversible) gender-affirming path, especially in TGDAs whose puberty has already progressed.

Study Information

Provider

pubmed

Year

2024

Date

2024-05-17T00:00:00.000Z

DOI

10.1210/clinem/dgad729